Robatumumab combination with chemotherapy aims for safe dosing in pediatric advanced solid tumors

Pediatric advanced solid tumors represent a significant challenge in oncology, often requiring aggressive treatment regimens. Current therapies, while effective for some, can be associated with severe toxicities and may not be curative for all patients, particularly those with advanced or recurrent disease. There is a critical need to identify novel therapeutic strategies, including combination approaches, that can improve outcomes while maintaining an acceptable safety profile in this vulnerable population. Combination therapies often aim to leverage synergistic effects or overcome resistance mechanisms, but their safety in children must be rigorously established.

This Phase 1/1B, non-randomized, open-label, dose-escalation study is evaluating robatumumab (SCH 717454, MK-7454) in combination with standard chemotherapy regimens in pediatric participants with advanced solid tumors. Three distinct treatment arms are planned: Arm A combines robatumumab with temozolomide and irinotecan; Arm B uses robatumumab with cyclophosphamide, doxorubicin, and vincristine; and Arm C pairs robatumumab with ifosfamide and etoposide. The primary objectives are to assess the safety, tolerability, and dose-finding of robatumumab in these combination therapies.

This abstract describes the protocol for a Phase 1/1B clinical trial and does not present specific results or findings.

The primary study hypothesis, as outlined, is that robatumumab can be safely administered in combination with various chemotherapy regimens in pediatric participants with advanced solid tumors. The study aims to determine the maximum tolerated dose and characterize the safety profile of these combination therapies. No efficacy data, specific adverse event rates, or pharmacokinetic parameters are reported in this protocol description.